TrialJournal of translational medicine2018

Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.

Erik Lindström et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.